Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 2, 2014, Pages 457-466

  Armbruster, Marco ^a   Zech, Christoph J ^a,b   Sourbron, Steven ^c   Ceelen, Felix ^a   Auernhammer, Christoph J ^a   Rist, Carsten ^a   Haug, Alexander ^a   Singnurkar, Amit ^d   Reiser, Maximilian F ^a   Sommer, Wieland H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

DCE MRI; diagnostic accuracy; liver metastases; neuroendocrine tumor; PET CT

Indexed keywords

DOTATATE GA 68; FLUORODEOXYGLUCOSE F 18; GADOXETIC ACID; IOMEPROL; TRACER; UNCLASSIFIED DRUG; 68GA-DOTATATE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER METASTASIS; MALE; NEUROENDOCRINE NEOPLASM; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING; VERY ELDERLY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904581317     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24363     Document Type: Article

References (40)

1. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61: 6-32.
2. Auernhammer CJ, Goke B,. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011; 60: 1009-1021.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
4. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL,. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97: 537-543.
5. Dunfee BL, Riaz A, Lewandowski RJ, et al. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol 2010; 21: 90-95.
6. Debray MP, Geoffroy O, Laissy JP, et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001; 74: 1065-1070. (Pubitemid 33121143)
7. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180: 121-128. (Pubitemid 36008698)
8. Sommer WH, Zech CJ, Bamberg F, et al. Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin. Eur J Radiol 2012; 81: 2127-2132.
9. d'Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 2013; 268: 390-399.
10. Sankowski AJ, Cwikla JB, Nowicki ML, et al. The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit 2012; 18: MT33-MT40.
11. Kim YK, Park G, Kim CS, Yu HC, Han YM,. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol 2012; 85: 539-547.
12. Van Beers BE, Pastor CM, Hussain HK,. Primovist, eovist: what to expect? J Hepatol 2012; 57: 421-429.
13. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO,. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6: 43-52.
14. Rufini V, Baum RP, Castaldi P, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 2012; 37: 1004-1020.
15. Koh TS, Thng CH, Lee PS, et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008; 249: 307-320.
16. Thng CH, Koh TS, Collins DJ, Koh DM,. Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 2010; 16: 1598-1609.
17. Sourbron S, Sommer WH, Reiser MF, Zech CJ,. Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 2012; 263: 874-883.
18. Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 2002; 47: 135-142. (Pubitemid 34019702)
19. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239.
20. Oberg K, Knigge U, Kwekkeboom D, Perren A,. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii124-130.
21. Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010; 51: 704-712.
22. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009; 50: 1927-1932.
23. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-1438.
24. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP,. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005; 32: 478-485.
25. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008; 112: 2447-2455.
26. Haug AR, Tiega Donfack BP, Trumm C, et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53: 371-377.
27. Fuccio C, Musto A, Cambioli S, et al. When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors? Clin Nucl Med 2011; 36: 1109-1111.
28. Sourbron S, Ingrisch M, Siefert A, Reiser M, Herrmann K,. Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med 2009; 62: 205-217.
29. Makkat S, Luypaert R, Stadnik T, et al. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings-preliminary results. Radiology 2008; 249: 471-482.
30. Do RK, Rusinek H, Taouli B,. Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. Magn Reson Imaging Clin N Am 2009; 17: 339-349.
31. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L,. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009; 29: 1323-1331.
32. Giesel FL, Kratochwil C, Mehndiratta A, et al. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 2012; 81: 2820-2825.
33. Pfannenberg C, Schraml C, Schwenzer N, et al. Comparison of [68Ga]DOTATOC-PET/CT and whole-body MRI in staging of neuroendocrine tumors. Cancer Imaging 2011; 11 (Spec No A): S38-S39.
34. Kamaya A, Maturen KE, Tye GA, Liu YI, Parti NN, Desser TS,. Hypervascular liver lesions. Semin Ultrasound CT MR 2009; 30: 387-407.
35. Scoazec JY,. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology 2013; 97: 45-56.
36. Weinmann HJ, Bauer H, Frenzel T, Muhler A, Ebert W,. Mechanism of hepatic uptake of gadoxetate disodium. Acad Radiol 1996;(Suppl 2): S232-S234.
37. Miyazaki K, Orton MR, Davidson RL, et al. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 2012; 263: 139-148.
38. Soret M, Bacharach SL, Buvat I,. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945. (Pubitemid 46909922)
39. Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 2012; 22: 458-467.
40. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. (Pubitemid 40139918)